BR112016015936A2 - Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição - Google Patents
Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composiçãoInfo
- Publication number
- BR112016015936A2 BR112016015936A2 BR112016015936A BR112016015936A BR112016015936A2 BR 112016015936 A2 BR112016015936 A2 BR 112016015936A2 BR 112016015936 A BR112016015936 A BR 112016015936A BR 112016015936 A BR112016015936 A BR 112016015936A BR 112016015936 A2 BR112016015936 A2 BR 112016015936A2
- Authority
- BR
- Brazil
- Prior art keywords
- mycobacterium
- vector
- immunogenic combination
- host cell
- antigens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1289—Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305030 | 2014-01-09 | ||
| PCT/EP2015/050344 WO2015104380A1 (en) | 2014-01-09 | 2015-01-09 | Fusion of heterooligomeric mycobacterial antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016015936A2 true BR112016015936A2 (pt) | 2017-09-19 |
Family
ID=49989636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016015936A BR112016015936A2 (pt) | 2014-01-09 | 2015-01-09 | Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10765731B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3092000A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6605480B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160130216A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106103471B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016015936A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2936131A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL246659A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016009072A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2695462C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201605595YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015104380A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201500171YA (en) * | 2012-07-10 | 2015-02-27 | Transgene Sa | Mycobacterial antigen vaccine |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| CN105218680B (zh) * | 2015-10-21 | 2019-06-25 | 中山大学 | 一种用于诱导外周血单个核细胞产生细胞因子的结核分支杆菌融合蛋白 |
| CN105601747B (zh) * | 2015-10-21 | 2019-05-28 | 中山大学 | 一种结核杆菌融合蛋白及其在诱导外周血单个核细胞产生细胞因子的应用 |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| EP3458088A2 (en) * | 2016-05-21 | 2019-03-27 | Infectious Disease Research Institute | Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections |
| AU2017280065B2 (en) | 2016-06-22 | 2021-07-01 | International Aids Vaccine Initiative, Inc. | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2019079155A1 (en) | 2017-10-17 | 2019-04-25 | International Aids Vaccine Initiative, Inc. | CASSETTES OF ANTIGENS OF TUBERCULOSIS |
| KR102004902B1 (ko) * | 2017-12-26 | 2019-07-29 | 연세대학교 산학협력단 | 융합 단백질을 포함하는 결핵 예방용 조성물 |
| CN110684116B (zh) * | 2019-08-23 | 2022-04-26 | 成都可恩生物科技有限公司 | 一种结核分枝杆菌eec融合蛋白、制备方法及其应用 |
| CN110590957B (zh) * | 2019-09-11 | 2021-06-01 | 中国人民解放军总医院第八医学中心 | 一种融合蛋白及其在抗结核分枝杆菌的免疫保护中的应用 |
| RU2724896C1 (ru) * | 2019-11-14 | 2020-06-26 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Полиантигенная вакцина для профилактики и вспомогательного лечения туберкулеза |
| CN111269297B (zh) * | 2020-01-23 | 2021-11-30 | 郑州伊美诺生物技术有限公司 | 一种结核分枝杆菌刺激抗原的制备方法 |
| CN116284283A (zh) * | 2021-12-13 | 2023-06-23 | 江苏瑞科生物技术股份有限公司 | 重组结核分枝杆菌抗原、其制备方法和应用 |
| IL318534A (en) * | 2022-08-03 | 2025-03-01 | BioNTech SE | RNA for preventing or treating tuberculosis |
| WO2024027910A1 (en) * | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
| CN116162141B (zh) * | 2022-11-30 | 2024-04-12 | 中国疾病预防控制中心传染病预防控制所 | 一种结核分枝杆菌抗原epcra013及其应用 |
| CN116063418B (zh) * | 2022-12-08 | 2024-04-12 | 中国疾病预防控制中心传染病预防控制所 | 结核分枝杆菌抗原组合物epdpa015及其制备方法与应用 |
| WO2024138121A2 (en) * | 2022-12-22 | 2024-06-27 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and vaccine for the prevention of tuberculosis or other mycobacterial infections |
| CN116106544A (zh) * | 2023-01-10 | 2023-05-12 | 南京农业大学 | 一种牛分枝杆菌抗体检测试剂盒 |
| CN117683141A (zh) * | 2023-10-27 | 2024-03-12 | 中国疾病预防控制中心传染病预防控制所 | 结核分枝杆菌多抗原融合蛋白及编码基因和应用 |
| US20250387462A1 (en) * | 2024-06-21 | 2025-12-25 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and vaccine for the prevention of tuberculosis or other mycobacterial infections |
| WO2026108990A1 (zh) * | 2024-11-21 | 2026-05-28 | 深圳瑞吉生物科技有限公司 | 一种防治结核病的mRNA药物组合物及其应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| DE69633565T3 (de) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| EP0988053A1 (en) | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| US6328978B1 (en) * | 1997-12-23 | 2001-12-11 | Genesis Research & Development Corp. Ltd. | Methods for the treatment of immunologically-mediated skin disorders |
| MXPA00006168A (es) * | 1997-12-23 | 2005-02-24 | Genesis Res & Dev Corp Ltd | Composiciones derivadas de mycrobacterium vaccae y metodos para su uso. |
| CA2364934C (fr) | 1999-02-22 | 2011-10-18 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| ATE519854T1 (de) | 1999-05-17 | 2011-08-15 | Crucell Holland Bv | Rekombinantes adenovirus auf basis von serotyp 48 (ad48). |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| AU2002317940B9 (en) | 2001-06-22 | 2008-06-05 | The Secretary Of State For Health | Mycobacterial antigens expressed under low oxygen tension |
| US7393540B2 (en) | 2001-07-04 | 2008-07-01 | Health Protection Agency | Mycobacterial antigens expressed during latency |
| UA82466C2 (uk) | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Спосіб посилення ампліфікації хордопоксвірусу |
| GB0125535D0 (en) | 2001-10-24 | 2001-12-12 | Microbiological Res Authority | Mycobacterial genes down-regulated during latency |
| US7094412B2 (en) | 2001-12-10 | 2006-08-22 | Bavarian Nordic A/S | Poxvirus containing formulations and process for preparing stable poxvirus containing compositions |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| WO2004006952A2 (en) | 2002-07-13 | 2004-01-22 | Statens Serum Institut | Therapeutic tuberculosis vaccines |
| US20040185555A1 (en) | 2003-03-17 | 2004-09-23 | Emini Emilio A. | Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby |
| EP1611237A1 (en) | 2003-03-28 | 2006-01-04 | Merck & Co., Inc. | Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby |
| WO2005061534A2 (en) | 2003-12-23 | 2005-07-07 | Statens Serum Institut | Improved tuberculosis vaccines |
| JP4814800B2 (ja) | 2004-01-23 | 2011-11-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | チンパンジーアデノウイルスワクチン担体 |
| AU2005285513B2 (en) * | 2004-05-25 | 2011-02-24 | Oregon Health And Science University | SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors |
| US20060024332A1 (en) | 2004-08-02 | 2006-02-02 | Waters Wade R | Recombinant ESAT-6:CFP-10 fusion protein useful for specific diagnosis of tuberculosis |
| EP1786460A4 (en) * | 2004-08-26 | 2008-04-02 | Sequella Inc | TEST FOR DETECTION OF TUBERCULOSIS IN NON-MENTAL PRIMATES |
| EA012436B1 (ru) * | 2005-01-05 | 2009-10-30 | Айсис Инновейшн Лимитед | Композиции для иммунизации против микобактерий |
| EA013016B1 (ru) | 2005-03-31 | 2010-02-26 | Лейден Юниверсити Медикал Сентер | Способы и средства диагностики, профилактики и лечения инфекций mycobacterium и заболевания туберкулезом |
| US7968105B2 (en) | 2005-06-23 | 2011-06-28 | Statens Serum Institut | Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
| EP1996732A4 (en) * | 2006-03-02 | 2010-03-31 | Uab Research Foundation | RECOGNITION AND TREATMENT AND DISCOVERY OF REMEDIES AGAINST MYCOBACTERIAL DISEASES |
| US20100129403A1 (en) | 2006-06-20 | 2010-05-27 | Transgene S.A. | Recombinant viral vaccine |
| WO2008124647A2 (en) * | 2007-04-04 | 2008-10-16 | Infectious Disease Research Institute | Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof |
| AU2008271756B2 (en) * | 2007-06-29 | 2012-10-04 | Statens Serum Institut | The use of monomycolyl glycerol (MMG) as an adjuvant |
| BRPI0811787B1 (pt) | 2007-07-03 | 2018-10-09 | Transgene Sa | usos de uma célula imortalizada e processo para imortalizar uma célula aviária |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| CN101376891B (zh) * | 2007-08-27 | 2012-05-23 | 上海生物制品研究所有限责任公司 | 新型结核病疫苗的制备及其应用 |
| US7935354B2 (en) | 2007-11-13 | 2011-05-03 | Aeras Global Tb Vaccine Foundation | Generation of new BCG vaccine strains protecting against the establishment of latent Mycobacterium tuberculosis infection and reactivation from the latent or persistent state |
| EP2353008A2 (en) | 2008-09-22 | 2011-08-10 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| WO2010034974A2 (en) * | 2008-09-24 | 2010-04-01 | Adjuvantix Limited | Tb vaccine |
| CN101538578B (zh) * | 2009-03-02 | 2011-01-26 | 华中农业大学 | 三基因融合的重组牛结核特异性抗原蛋白及制备方法 |
| EP2421557B1 (en) * | 2009-04-24 | 2018-12-05 | Statens Serum Institut | A tuberculosis tb vaccine to prevent reactivation |
| SG176554A1 (en) | 2009-05-12 | 2012-01-30 | Transgene Sa | Method for orthopoxvirus production and purification |
| ES2661215T3 (es) | 2009-05-20 | 2018-03-28 | Aeras | Composiciones víricas; inmunógenas; secadas por pulverización; estables |
| GB201007790D0 (en) * | 2010-05-10 | 2010-06-23 | Isis Innovation | Compositions |
| GB201008512D0 (en) * | 2010-05-21 | 2010-07-07 | Health Prot Agency | Mycobacterial antigen composition |
| CN101900727A (zh) * | 2010-06-01 | 2010-12-01 | 华中农业大学 | 一种应用Rv3872新型融合蛋白制备的牛结核抗体鉴别检测试纸条 |
| WO2012031752A2 (en) | 2010-09-07 | 2012-03-15 | Institut Pasteur Korea | Tuberculosis mutants |
| US20130345079A1 (en) | 2010-10-27 | 2013-12-26 | Infectious Disease Research Institute | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity |
| US20120244155A1 (en) | 2011-03-22 | 2012-09-27 | Baylor Research Institute | Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine |
| CN102692509B (zh) * | 2012-05-11 | 2014-11-26 | 中国农业科学院北京畜牧兽医研究所 | 重组蛋白混合物介导的牛结核病诊断方法及其试剂 |
| WO2014009433A1 (en) * | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| SG11201500171YA (en) | 2012-07-10 | 2015-02-27 | Transgene Sa | Mycobacterial antigen vaccine |
| CN102719438B (zh) * | 2012-07-12 | 2013-10-30 | 章晓联 | 一种能特异结合结核菌抗原的核酸适配子及其应用 |
| EP2912056B1 (en) * | 2012-10-23 | 2020-02-12 | Statens Serum Institut | M. tuberculosis vaccines |
| CN103333251B (zh) * | 2013-04-11 | 2014-08-20 | 广西壮族自治区动物疫病预防控制中心 | 基于重组融合抗原蛋白的γ-干扰素夹心ELISA检测方法 |
| CN103204945A (zh) * | 2013-05-03 | 2013-07-17 | 扬州大学 | 一种用于牛结核病诊断的真核表达cfp10-esat-6融合蛋白 |
| EP3013364B1 (en) | 2013-06-25 | 2022-08-03 | International AIDS Vaccine Initiative, Inc. | Tuberculosis compositions and methods of using the same |
| CN103386128B (zh) * | 2013-07-02 | 2017-02-08 | 中国食品药品检定研究院 | 一种含联合佐剂的结核亚单位疫苗 |
-
2015
- 2015-01-09 EP EP15700284.1A patent/EP3092000A1/en not_active Withdrawn
- 2015-01-09 JP JP2016545896A patent/JP6605480B2/ja not_active Expired - Fee Related
- 2015-01-09 CN CN201580012192.0A patent/CN106103471B/zh not_active Expired - Fee Related
- 2015-01-09 BR BR112016015936A patent/BR112016015936A2/pt not_active Application Discontinuation
- 2015-01-09 US US15/110,514 patent/US10765731B2/en active Active
- 2015-01-09 SG SG11201605595YA patent/SG11201605595YA/en unknown
- 2015-01-09 KR KR1020167020984A patent/KR20160130216A/ko not_active Ceased
- 2015-01-09 WO PCT/EP2015/050344 patent/WO2015104380A1/en not_active Ceased
- 2015-01-09 CA CA2936131A patent/CA2936131A1/en not_active Abandoned
- 2015-01-09 RU RU2016131853A patent/RU2695462C2/ru not_active IP Right Cessation
- 2015-01-09 MX MX2016009072A patent/MX2016009072A/es unknown
-
2016
- 2016-07-07 IL IL246659A patent/IL246659A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016131853A3 (cg-RX-API-DMAC7.html) | 2018-06-26 |
| CN106103471A (zh) | 2016-11-09 |
| CA2936131A1 (en) | 2015-07-16 |
| MX2016009072A (es) | 2017-05-08 |
| CN106103471B (zh) | 2020-01-07 |
| JP2017505605A (ja) | 2017-02-23 |
| EP3092000A1 (en) | 2016-11-16 |
| US20160331823A1 (en) | 2016-11-17 |
| IL246659A0 (en) | 2016-08-31 |
| US10765731B2 (en) | 2020-09-08 |
| KR20160130216A (ko) | 2016-11-10 |
| JP6605480B2 (ja) | 2019-11-13 |
| WO2015104380A1 (en) | 2015-07-16 |
| SG11201605595YA (en) | 2016-08-30 |
| RU2695462C2 (ru) | 2019-07-23 |
| RU2016131853A (ru) | 2018-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016009072A (es) | Fusion de antigenos micobacterianos heterooligomericos. | |
| AR090056A1 (es) | Anticuerpos anti-cxcr3 | |
| AR134186A2 (es) | Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora | |
| BR112016030424A2 (pt) | construções de anticorpo multiespecíficas | |
| EA201590184A1 (ru) | Вакцина на основе микобактериальных антигенов | |
| BR112019007288A2 (pt) | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente | |
| BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
| MY176332A (en) | Multispecific antibody constructs | |
| BR112017008693A2 (pt) | célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição. | |
| BR112015019603A2 (pt) | Moléculas de ácido nucleico isoladas, molécula de polipeptídeo isolada, molécula isolada de car, domínio de ligação anti-egfrviii, vetor, célula e uso de uma quantidade eficaz da mesma e métodos para produção de uma célula e para a produção de uma população de células modificadas por rna | |
| BR112016019068A2 (pt) | construto, vetor recombinante, composição farmacêutica, método de inibição de replicação viral ou expressão de uma sequência alvo em uma célula infectada com um vírus, polipeptídeo de sau cas9 recombinante, construto de sau cas9 recombinante, construto recombinante para expressão de um rna guia individual e kit | |
| BR112016024579A2 (pt) | métodos para isolamento, cultura e engenharia genética de populações de célula imune para terapia adotiva | |
| BR112018001572A2 (pt) | método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo. | |
| BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
| CN106715699A8 (zh) | 用于减弱抗病毒转移载体免疫应答的方法和组合物 | |
| BR112017014031A2 (pt) | n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado. | |
| BR112013031892A2 (pt) | anticorpos anti-psgl-1 e seu uso | |
| BR112018077358A2 (pt) | tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma | |
| BR112016015678A2 (pt) | Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso | |
| BR112016020517A2 (pt) | método de produção de lipídeo através da utilização de ss-cetoacil-acp sintase | |
| EA201391183A1 (ru) | Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин | |
| BR112016030326A2 (pt) | ?poliepítopo quimérico, polinucleotídeo, vetores, célula, partículas de vírus, composição imunogênica, método para prevenir e/ou tratar infecções e método de produção de partículas de mv? | |
| BR112015000585A8 (pt) | método para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante, vacina, kit de vacinação e usos do vetor e da cepa mutante | |
| BR112017025923A2 (pt) | molécula de ácido nucleico recombinante, molécula de aminoácido recombinante, construto de expressão recombinante, vetor recombinante, micro-organismo recombinante, composição, métodos para produção de um micro-organismo recombinante e para cultivo e crescimento de um micro-organismo geneticamente modificado, uso de uma molécula de ácido nucleico recombinante, e, processo para produção fermentativa de um composto. | |
| BR112015030655A2 (pt) | Variantes de xilanase e polinucleótidos que codificam as mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |